Immunomodulatory drugs regulate HMGB1 release from activated human monocytes

Molecular Medicine

Volumn 16, Issue 9-10, 2010, Pages 343-351

  Schierbeck, Hanna ^a,b   Wähämaa, Heidi ^a,b   Andersson, Ulf ^a,b   Harris, Helena Erlandsson ^a,b  

^a KAROLINSKA INSTITUTE   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRHEUMATIC AGENT; AUROTHIOMALATE; CHLOROQUINE; COLCHICINE; CORTISONE; CYTOKINE; DEXAMETHASONE; ETANERCEPT; GAMMA INTERFERON; HIGH MOBILITY GROUP B1 PROTEIN; IMMUNOMODULATING AGENT; LIPOPOLYSACCHARIDE; METHOTREXATE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; TUMOR NECROSIS FACTOR;

ARTICLE; CELL ACTIVATION; CELL CULTURE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DOWN REGULATION; DRUG MECHANISM; ENZYME LINKED IMMUNOSPOT ASSAY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IMMUNOREGULATION; IN VITRO STUDY; MONOCYTE; PRIORITY JOURNAL; PROTEIN SECRETION; PROTEIN SYNTHESIS INHIBITION; REGULATORY MECHANISM;

ANIMALS; CELLS, CULTURED; CHLOROQUINE; COLCHICINE; CORTISONE; DEXAMETHASONE; DOWN-REGULATION; GOLD SODIUM THIOMALATE; HMGB1 PROTEIN; HUMANS; IMMUNOLOGIC FACTORS; INTERLEUKIN-1BETA; INTRACELLULAR SPACE; METHOTREXATE; MICE; MONOCYTES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 77956624951     PISSN: 10761551     EISSN: None     Source Type: Journal    
DOI: 10.2119/molmed.2010.00031     Document Type: Article

References (42)

1. Yang H, Tracey KJ. Targeting HMGB1 in inflammation. Biochim. Biophys. Acta. 1799:149-56.
2. Andersson U, Harris HE. The role of HMGB1 in the pathogenesis of rheumatic disease. Biochim. Biophys. Acta. 1799:141-8.
3. Semino C, Angelini G, Poggi A, Rubartelli A. (2005) NK/iDC interaction results in IL-18 secretion by DCs at the synaptic cleft followed by NK cell activation and release of the DC maturation factor HMGB1. Blood. 106:609-16.
4. Wang H, et al. (1999) HMG-1 as a late mediator of endotoxin lethality in mice. Science. 285:248-51.
5. Wang H, et al. (1999) Proinflammatory cytokines (tumor necrosis factor and interleukin 1) stimulate release of high mobility group protein-1 by pituicytes. Surgery. 126:389-92.
6. Rendon-Mitchell B, et al. (2003) IFN-gamma induces high mobility group box 1 protein release partly through a TNF-dependent mechanism. J. Immunol. 170:3890-7.
7. Tang D, et al. (2007) The anti-inflammatory effects of heat shock protein 72 involve inhibition of high-mobility-group box 1 release and proinflammatory function in macrophages. J. Immunol. 179:1236-44.
8. Oh YJ, et al. (2009) HMGB1 is phosphorylated by classical protein kinase C and is secreted by a calcium-dependent mechanism. J. Immunol. 182:5800-9.
9. Kawahara K, et al. (2008) C-reactive protein induces high-mobility group box-1 protein release through activation of p38MAPK in macrophage RAW264.7 cells. Cardiovasc. Pathol. 17:129-38.
10. Youn JH, Shin JS. (2006) Nucleocytoplasmic shuttling of HMGB1 is regulated by phosphorylation that redirects it toward secretion. J. Immunol. 177:7889-97.
11. Bonaldi T, et al. (2003) Monocytic cells hyperacetylate chromatin protein HMGB1 to redirect it towards secretion. Embo. J. 22:5551-60.
12. Gardella S, et al. (2002) The nuclear protein HMGB1 is secreted by monocytes via a nonclassical, vesicle-mediated secretory pathway. EMBO Rep. 3:995-1001.
13. Harris HE, Raucci A. (2006) Alarmin(g) news about danger: workshop on innate danger signals and HMGB1. EMBO Rep. 7:774-8.
14. Touqui L, Alaoui-El-Azher M. (2001) Mammalian secreted phospholipases A2 and their pathophysiological significance in inflammatory diseases. Curr. Mol. Med. 1:739-54.
15. Scaffidi P, Misteli T, Bianchi ME. (2002) Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature. 418:191-5.
16. Bell CW, Jiang W, Reich CF 3rd, Pisetsky DS. (2006) The extracellular release of HMGB1 during apoptotic cell death. Am. J. Physiol. Cell Physiol. 291:C1318-25.
17. Schroder K, Hertzog PJ, Ravasi T, Hume DA. (2004) Interferon-gamma: an overview of signals, mechanisms and functions. J. Leukoc. Biol. 75:163-89.
18. Wahamaa H, et al. (2007) HMGB1-secreting capacity of multiple cell lineages revealed by a novel HMGB1 ELISPOT assay. J. Leukoc. Biol. 81:129-36.
19. Lotze MT, Tracey KJ. (2005) High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal. Nat. Rev. Immunol. 5:331-42.
20. Czock D, Keller F, Rasche FM, Haussler U. (2005) Pharmacokinetics and pharmacodynamics of systemically administered glucocorticoids. Clin. Pharmacokinet. 44:61-98.
21. Shiozawa K, et al. (2005) Serum levels and pharmacodynamics of methotrexate and its metabolite 7-hydroxy methotrexate in Japanese patients with rheumatoid arthritis treated with 2-mg capsule of methotrexate three times per week. Mod. Rheumatol. 15:405-9.
22. Korth-Bradley JM, Rubin AS, Hanna RK, Simcoe DK, Lebsack ME. (2000) The pharmacokinetics of etanercept in healthy volunteers. Ann. Pharmacother. 34:161-4.
23. Granowitz EV, et al. (1992) Pharmacokinetics, safety and immunomodulatory effects of human recombinant interleukin-1 receptor antagonist in healthy humans. Cytokine. 4:353-60.
24. Yang H, et al. (2004) Reversing established sepsis with antagonists of endogenous high-mobility group box 1. Proc. Natl. Acad. Sci. U. S. A. 101:296-301.
25. Abraham E, Arcaroli J, Carmody A, Wang H, Tracey KJ. (2000) HMG-1 as a mediator of acute lung inflammation. J. Immunol. 165:2950-4.
26. Kim JY, et al. (2005) HMGB1 contributes to the development of acute lung injury after hemorrhage. Am. J. Physiol. Lung Cell. Mol. Physiol. 288:L958-L965.
27. Liu K, et al. (2007) Anti-high mobility group box 1 monoclonal antibody ameliorates brain infarction induced by transient ischemia in rats. Faseb. J. 21:3904-16.
28. Van de Wouwer M, et al. (2006) The lectin-like domain of thrombomodulin interferes with complement activation and protects against arthritis. J. Thromb. Haemost. 4:1813-24.
29. Hofmann MA, et al. (2002) RAGE and arthritis: the G82S polymorphism amplifies the inflammatory response. Genes Immun. 3:123-35.
30. Kokkola R, et al. (2003) Successful treatment of collagen-induced arthritis in mice and rats by targeting extracellular high mobility group box chromosomal protein 1 activity. Arthritis Rheum. 48:2052-8.
31. Lutterloh EC, et al. (2007) Inhibition of the RAGE products increases survival in experimental models of severe sepsis and systemic infection. Crit. Care. 11:R122
32. Huston JM, et al. (2007) Transcutaneous vagus nerve stimulation reduces serum high mobility group box 1 levels and improves survival in murine sepsis. Crit. Care Med. 35:2762-8.
33. Pan P, et al. (2009) Low-dose cisplatin administration in murine cecal ligation and puncture prevents the systemic release of HMGB1 and attenuates lethality. J. Leukoc. Biol. 86:625-32.
34. Ostberg T, et al. (2008) Oxaliplatin retains HMGB1 intranuclearly and ameliorates collagen type II-induced arthritis. Arthritis Res. Ther. 10:R1.
35. af Klint E, et al. (2005) Intraarticular glucocorticoid treatment reduces inflammation in synovial cell infiltrations more efficiently than in synovial blood vessels. Arthritis Rheum. 52:3880-9.
36. Thieringer R, et al. (2001) 11 Beta-hydroxysteroid dehydrogenase type 1 is induced in human monocytes upon differentiation to macrophages. J. Immunol. 167:30-5.
37. Zetterstrom CK, et al. (2008) Pivotal advance: inhibition of HMGB1 nuclear translocation as a mechanism for the anti-rheumatic effects of gold sodium thiomalate. J. Leukoc. Biol. 83:31-8.
38. French JK, Hurst NP, O'Donnell ML, Betts WH. (1987) Uptake of chloroquine and hydroxychloroquine by human blood leucocytes in vitro: relation to cellular concentrations during antirheumatic therapy. Ann. Rheum. Dis. 46:42-5.
39. Tett S, Cutler D, Day R. (1990) Antimalarials in rheumatic diseases. Baillieres Clin. Rheumatol. 4:467-89.
40. Lange F, et al. (2005) Methotrexate ameliorates T cell dependent autoimmune arthritis and encephalomyelitis but not antibody induced or fibroblast induced arthritis. Ann. Rheum. Dis. 64:599-605.
41. Sundberg E, et al. (2008) Systemic TNF blockade does not modulate synovial expression of the pro-inflammatory mediator HMGB1 in rheumatoid arthritis patients-a prospective clinical study. Arthritis Res. Ther. 10:R33.
42. Sha Y, Zmijewski J, Xu Z, Abraham E. (2008) HMGB1 develops enhanced proinflammatory activity by binding to cytokines. J. Immunol. 180:2531-7.